MNGO-18. SCHWANNOMA RESPONSE TO CONCURRENT TREATMENT WITH INTERFERON ALPHA FOR METASTASTIC MELANOMA: A CASE REPORT Wendy Sherman and Todd Vitaz; Spectrum Health, Grand Rapids, MI, USA
a combination of the two modalities. There is no defined role for medical therapy, though perhaps there is a need as these treatment modalities can result in neurologic deficits in this patient population. We present a case of a patient with a cerebellopontine (CP) angle tumor identified during staging for metastatic melanoma after presenting with ipsilateral trigeminal neuralgia. He was treated with one month of interferon alpha for his metastatic melanoma with subsequent partial response of his CP angle tumor, though was ultimately resected given intractable trigeminal neuralgia. Interferon alpha has been studied in meningiomas, overall demonstrating moderate toxicity with limited efficacy, despite anti-proliferation activity in in-vitro studies. This case study demonstrating a partial response in a patient with schwannoma and should be considered for future studies in patients with recurrent disease after surgery and radiation or in patients where those modalities are not indicated.
Non-malignant schwannomas are typically treated with surgery, radiation, or
Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2015.
